Introduction A collaboration of the CML Advocates Network / Leukaemia Patient Advocates Foundation with a major pharmaceutical company regarding the use of a medicine in Phase III trials (adult...
Patient engagement in medicines development: Recommendations on how to find the right match for the right patient engagement activity. Background/Rationale for the document During the analysis of existing practices...
Transcription So my name is Virginie Hivert, I’m working for EURORDIS, the European organisation for rare disease patients. I’m the Therapeutic Development Director, and so I’m a patient...
Nanoparticles are tiny objects, available only as intravenous formulations, that help medicines get to difficult-to-reach cells and tissue. They can also help protect molecules and control the targeted release...
Transcription My name is Pauline Kitchiner, and I work at GSK’s Clinical Unit in Cambridge. Which is a purpose built clinical unit to conduct phase one or phase...
Authors: Oyiza Momoh, Susan W. Burriss, Anya Harry, Kay Warner The importance of inclusion and diversity in clinical trials It is important that people participating in clinical trials...
Note: This webinar took place on 5 July 2017. You can find a video recording and the presentations used during the webinar below. Webinar introduction A very important result from the...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
